Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Injectable Zyprexa Approved

Suppresses acute agitation

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

WEDNESDAY, March 31, 2004 (HealthDayNews) -- An injectable form of Eli Lilly's best-selling antipsychotic drug Zyprexa has won approval from the U.S. Food and Drug Administration.

In injectable form, the drug gives doctors a faster-acting option to control the acute agitation that can cripple people with schizophrenia or bipolar disorder, sometimes referred to as manic depression, the company says in a prepared statement.

Acute agitation can be characterized by hostility, extreme excitement, and uncooperativeness. A 10-milligram injection of Zyprexa IntraMuscular can calm a patient in as few as 15 minutes, the company says. The product is most likely to be used in hospital emergency rooms.

Zyprexa becomes the second injectable medication in its class to be marketed, following FDA approval of Pfizer's Geodon in 2002.

The oral form of Zyprexa, along with several other similar drugs, was included in an FDA labeling change announced earlier this month. The agency warned that users of these medications could be at greater risk of diabetes.


Last Updated: